Paroxysmal Nocturnal Haemoglobinuria (PNH) Dr Conal McConville ...

Summary of Clinical Efficacy
In clinical trials, SOLIRIS ® significantly reduced haemolysis 1
the underlying cause of morbidity and mortality in PNH
• 86% sustained reduction in haemolysis as measured by LDH 2
• 92% reduction in thrombotic events across all patient types 3
• 94% reduction in thrombotic events in patients treated with
anticoagulants 3
• Patients treated with SOLIRIS experienced improvement in CKD and
pulmonary hypertension 4,5
• 78% clinically meaningful improvement in fatigue
– Fatigue in PNH impacted by haemolysis
– Significant improvement noted in pain and dyspnoea along with a
broad range of QoL measures 5
• 73% reduction in need for transfusions across all patient populations
2
1. SOLIRIS® (eculizumab) [package insert]. Alexion Pharmaceuticals; 2009. 2. Hillmen P et al. N Engl J Med. 2006;355:1233-43. 3. Hillmen P et al. Blood. 2007;110(12):4123-8. 4. Hillmen P et al. Am. J. Hematol. 2010; 85:553–559 5.
Hill A, et al. BJH. doi:10.1111/j.1365-2141.2010 5. Socie G et al. Blood. 2007;110(11)::Abstract 3672.
August 12_10_2010Gbl
28